- Home
- MERC vs NGNE Comparison
MERC vs NGNE Comparison
Compare MERC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MERC
- NGNE
- Stock Information
- Founded
- MERC 1968
- NGNE 2003
- Country
- MERC Canada
- NGNE United States
- Employees
- MERC N/A
- NGNE N/A
- Industry
- MERC Paper
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- MERC Basic Materials
- NGNE Health Care
- Exchange
- MERC Nasdaq
- NGNE Nasdaq
- Market Cap
- MERC 271.5M
- NGNE 325.3M
- IPO Year
- MERC 1987
- NGNE N/A
- Fundamental
- Price
- MERC $3.05
- NGNE $17.71
- Analyst Decision
- MERC Hold
- NGNE Strong Buy
- Analyst Count
- MERC 3
- NGNE 7
- Target Price
- MERC $4.67
- NGNE $41.86
- AVG Volume (30 Days)
- MERC 484.3K
- NGNE 133.6K
- Earning Date
- MERC 10-30-2025
- NGNE 11-14-2025
- Dividend Yield
- MERC 9.74%
- NGNE N/A
- EPS Growth
- MERC N/A
- NGNE N/A
- EPS
- MERC N/A
- NGNE N/A
- Revenue
- MERC $1,951,044,000.00
- NGNE N/A
- Revenue This Year
- MERC N/A
- NGNE N/A
- Revenue Next Year
- MERC $13.33
- NGNE N/A
- P/E Ratio
- MERC N/A
- NGNE N/A
- Revenue Growth
- MERC N/A
- NGNE N/A
- 52 Week Low
- MERC $2.59
- NGNE $6.88
- 52 Week High
- MERC $8.28
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- MERC 42.99
- NGNE 38.90
- Support Level
- MERC $3.07
- NGNE $17.13
- Resistance Level
- MERC $3.29
- NGNE $20.72
- Average True Range (ATR)
- MERC 0.14
- NGNE 1.29
- MACD
- MERC 0.00
- NGNE -0.18
- Stochastic Oscillator
- MERC 5.71
- NGNE 16.20
About MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.